SARMS LGD4033 For Bodybuilding CAS:1165910-22-4
LGD4033 is a SARM (Selective Androgen Receptor Modulator). It's known for promoting muscle growth and bone density without the severe side effects of steroids. For LGD4033, the key points would be its selectivity for muscle and bone tissues, its use in medical research for muscle wasting and osteoporosis, and its popularity in bodybuilding. Features: High selectivity, non-steroidal, oral bioavailability. Applications: Muscle wasting conditions, osteoporosis, athletic performance. Benefits: Muscle growth, fat loss, minimal androgenic side effects. Dosage: Typically 5-10 mg/day. Cycle: 8-12 weeks. Half-life: Around 24-36 hours. PCT: Needed due to testosterone suppression.
LGD-4033, known as Ligandrol, is a third-generation Selective Androgen Receptor Modulator (SARM) developed by Ligand Pharmaceuticals in collaboration with Viking Therapeutics. Initially investigated for treating muscle wasting and osteoporosis, LGD-4033 has gained prominence for its ability to selectively activate androgen receptors (AR) in muscle and bone while sparing prostate and sebaceous tissues. Unlike traditional anabolic steroids, Ligandrol's tissue specificity and oral efficacy make it a cornerstone in both therapeutic research and performance enhancement, offering a safer alternative to conventional androgen therapies.
Molecular Architecture and Mechanism: Precision in Action
Chemical Profile
●IUPAC Name: (2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
●Molecular Formula: C₁₄H₁₂F₃N₃O₃
●Molecular Weight: 343.26 g/mol
●Solubility: Lipophilic (soluble in DMSO, PEG-300); negligible aqueous solubility.
Mechanistic Insights
LGD-4033 binds ARs with high affinity (Ki = 1.2 nM), acting as a full agonist in muscle and bone tissues. Key pathways include:
●mTORC1 Activation: Stimulates ribosomal S6 kinase, enhancing protein synthesis.
●Osteoblast Stimulation: Upregulates Wnt/β-catenin signaling, increasing bone mineral density (BMD).
●Anti-Catabolic Effects: Inhibits glucocorticoid-induced muscle degradation via AR interference.
Unique Pharmacodynamics
●Non-Steroidal Structure: Avoids 5α-reduction, eliminating dihydrotestosterone (DHT)-linked side effects (e.g., acne, prostate enlargement).
●Blood-Brain Barrier Penetration: Modulates central ARs to enhance neuromuscular drive and appetite regulation.
●CYP3A4 Resistance: High oral bioavailability (~94%) due to nitro-group shielding from hepatic metabolism.
Applications: From Clinical Therapy to Biohacking
Therapeutic Innovations
1.Cancer Cachexia:
●In Phase II trials, 1 mg/day for 21 days increased lean mass by 1.3 kg in advanced cancer patients, outperforming placebo by 300%.
2.Osteoporosis Rehabilitation:
●Improved trabecular BMD by 12% in osteopenic rats (0.3 mg/kg/day for 8 weeks).
3.Age-Related Sarcopenia:
●Elderly men (65+) gained 3.1% lean mass with 2 mg/day over 12 weeks, sans lipid or PSA changes.
Athletic and Aesthetic Enhancement
●Lean Mass Accretion: Anecdotal reports suggest 4–7 lbs of muscle gain over 8 weeks at 5–10 mg/day.
●Strength Gains: Powerlifters note 8–12% improvements in 1RM lifts via enhanced myosin ATPase efficiency.
●Injury Recovery: Accelerates tendon repair by upregulating collagen synthesis in preclinical models.
Emerging Frontiers
●Neuroprotection: Preserves motor neurons in ALS models via AR-dependent SOD1 modulation.
●Metabolic Health: Enhances insulin sensitivity in adipose tissue through PI3K-Akt crosstalk.
●Space Medicine: Mitigates microgravity-induced atrophy in NASA-funded rodent studies.
Benefits and Risks: A Balanced Perspective
Advantages
●Tissue Selectivity: 10:1 anabolic-to-androgenic ratio, surpassing testosterone's 1:1 profile.
●Oral Efficacy: No injections required, with stable plasma levels over 24 hours.
●Muscle Memory: Upregulates MyoD expression, enhancing rebound growth post-cycle.
Risks and Controversies
●HPTA Suppression: Doses ≥5 mg/day reduce LH/FSH by 50–70%, necessitating PCT.
●Lipid Dysregulation: HDL suppression (-20%) and LDL elevation (+15%) in 12-week cycles.
●AR Desensitization: Chronic use (>6 months) downregulates muscle AR density by 30%.
Dosage and Cycle Design: Precision Protocols
Clinical and Anecdotal Guidelines
●Muscle Growth: 5–10 mg/day for 8–12 weeks (split AM/PM doses).
●Medical Use: 1–2 mg/day for osteoporosis or cachexia.
●Female Protocols: 2.5 mg/day for lean gains without virilization (voice deepening risk <1%).
Critical Note: Avoid grapefruit (CYP3A4 inhibitor) and high-fat meals (delays Tmax by 45 mins).
Synergistic Stacks and Cycle Architecture
Solo Cycle Framework
●Weeks 1–8: 5 mg/day, AM dosing.
●PCT Protocol: 10 mg Tamoxifen + 25 mg Clomid daily for 3 weeks post-cycle.
Strategic Synergies
1.LGD-4033 + MK-677: Combines hypertrophy with GH-driven recovery (5 mg LGD + 25 mg MK-677).
2.LGD-4033 + Cardarine: Targets fat loss (5 mg LGD + 20 mg GW501516).
3.Neuroprotective Stack: LGD-4033 (5 mg) + Lion's Mane (1g) for cognitive benefits.
Pharmacokinetics and Temporal Dynamics
●Absorption: Tmax = 1–2 hours; bioavailability unaffected by food.
●Half-Life: ~24–36 hours, supporting once-daily dosing.
●Metabolism: Hepatic UGT2B17 glucuronidation; excreted renally (65%) and fecally (35%).
Genetic Note: UGT2B17 polymorphisms (common in East Asians) reduce clearance by 40%.
Post-Cycle Therapy (PCT): Restoring Homeostasis
●Hormonal Recovery: SERMs like Tamoxifen (20 mg/day) or Enclomiphene (12.5 mg/day) for 3–4 weeks.
●Lipid Rehabilitation: Bergamot extract (1,000 mg/day) or omega-3s (4g EPA/DHA) for 6 weeks.
●Muscle Retention: Leucine (5g/day) to sustain mTOR activity post-cycle.
Novel Insights: Uncharted Research Directions
Epigenetic Modulation
LGD-4033 demethylates AR promoters in satellite cells, creating a "muscle memory" effect lasting 6+ months.
Gut-Microbiome Axis
Alters Lactobacillus reuteri populations, enhancing systemic BCAA availability and nitrogen retention.
Cardiovascular Paradox
While lowering HDL, LGD-4033 upregulates endothelial nitric oxide synthase (eNOS), improving vascular function.
Ethical and Regulatory Considerations
●WADA Status: Banned since 2015 for performance enhancement.
●Legal Ambiguity: Marketed as a "research chemical," evading FDA oversight despite human use.
●Environmental Impact: Non-biodegradable metabolites detected in aquatic ecosystems.
Future Horizons: The Next Era of SARMs
●Prodrug Development: LGD-4033 palmitate for weekly dosing via subcutaneous depots.
●CRISPR Synergy: Gene-edited AR expression to amplify tissue-specific effects.
●Clinical Trials: Urgent need for Phase III studies in cachexia and osteoporosis populations.
Clinical data
|
Trade names |
LGD4033,Ligandrol,VK5211 |
|
CAS |
1165910-22-4 |
|
Molar mass |
338.253 |
|
MF |
C14H12F6N2O |
|
Purity |
Above 98% |
|
Apprarance |
10mg*100 Tablets |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion: Redefining Muscle Therapeutics
LGD-4033 epitomizes the potential of SARMs-delivering targeted anabolism with minimized side effects. Its role in treating muscle wasting, enhancing performance, and combating aging underscores the need for rigorous research and ethical use. As science advances, LGD-4033 may revolutionize how we approach muscle health, bridging gaps between clinical therapy and human potential.
Hot Tags: sarms lgd4033 for bodybuilding cas:1165910-22-4, China sarms lgd4033 for bodybuilding cas:1165910-22-4 manufacturers, suppliers, factory, GW0742 Hormone and Metabolic Regulators, MK2866 Treat Muscular Dystrophy and Osteoporosis, LGD4033 Treat Muscular Dystrophy and Osteoporosis, OTR-AC, S23, MK2866
